The FDA has approved Tracleer (bonestan) tablets for the treatment of pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the lungs. Developed by Alembic Pharmaceuticals Ltd., bosentan 62.5 mg and 125 mg tablets have been found effective at treating PAH.
The FDA announced last week an accelerated approval of Tazverik (tazemetostat) for the treatment of metastatic and locally advanced epithelioid sarcoma, a soft tissue cancer, for patients above 16 years. Epithelioid sarcoma is a rare soft tissue cancer that affects younger adults.
A new study, which appeared in Cell Reports, has found that a gut microbiome could help in preventing and even reversing Parkinson’s disease, an incurable neurological condition. Researchers found that a gut bacterium clears the clumping of a protein associated with Parkinson’s disease.
The FDA released a Complete Response Letter (CRL) to Sarepta Therapeutics on the agency’s website over its drug called golodirsen (Vyondys 53) for the treatment of Duchene muscular dystrophy. The letter mentioned the potential risk of infection and renal toxicity of the drug.
California regulators are considering deeming the drug acetaminophen (Tylenol) as a carcinogen. Although there have been mixed results, some studies have found that acetaminophen increased the risk of certain cancers, such as blood, kidney, and bladder cancer. However, the evidence is unclear.
In the latest bidding of China’s bulk-buy program that took place on Friday, global pharma companies and generic drugmakers slashed their prices by 53% on some of their off-patent drugs. The national bulk-buy program’s goal is to get medications at the lowest possible prices at public hospitals and medical centers.
A new study has found that a class of antibiotic drugs called aminoglycosides could be effective a treating early-onset dementias such as frontotemporal dementia or frontotemporal lobar dementia. The study found that the antibiotic fixed the genetic mutation associated with dementia.